Hopp til innhold
NHI.no
Annonse

Korea: Prognose

Huntingtons korea er en kronisk og alvorlig sykdom med stadig forverring over tid, etter hvert utvikles også demens. Antall leveår etter sykdomsstart anslås til å være 10-25 år. Sydenhams korea er forbigående og varer vanligvis 10-15 uker. Medikamentell korea bedres etter at man slutter med det utløsende medikamentet.

Annonse

Dette dokumentet er basert på det profesjonelle dokumentet Huntingtons sykdom . Referanselisten for dette dokumentet vises nedenfor

  1. Revilla FJ. Huntington disease. Medscape, last updated Feb 27, 2019. emedicine.medscape.com
  2. Huntington G. On chorea. Med Surg Report. 1872. 26:320.
  3. Pringsheim T, Wiltshire K, Day L, Dykeman J, Steeves T, Jette N. The incidence and prevalence of Huntington's disease: a systematic review and meta-analysis. Mov Disord. 2012 Aug. 27 (9):1083-91. PMID: 22692795. PubMed
  4. Heiberg A. Huntingtons sykdom. Tidsskr Nor Legeforen 2008; 128: 2214-7. Tidsskrift for Den norske legeforening
  5. Suchowersky O. Huntington disease: Clinical features and diagnosis. UpToDate, last updated Sep 08, 2021. UpToDate
  6. Loy CT, McCusker EA. Is a motor criterion essential for the diagnosis of clinical Huntington disease?. PLoS Curr. 2013 April 11. doi:10.1371/currents.hd.f4c66bd51e8db11f55e1701af937a419 DOI
  7. Suchowersky O. Huntington disease: Management. UpToDate, last updated Mar 08, 2022. UpToDate
  8. Schultz JL, Ogilvie AC, Harshman LA, Nopoulos PC. β-Blocker Use and Delayed Onset and Progression of Huntington Disease. JAMA Neurol. 2025 Jan 1;82(1):85-92. PMID: 39621338. PubMed
  9. Huntington Study Group TREND-HD Investigators. Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study. Arch Neurol 2008; 65: 1582-9. PubMed
  10. Roos RA, Hermans J, van der Vegter V, van Ommen GJ, Bruyn GW. Duration of illness in Huntington's disease is not related to age at onset. J Neurol Neurosurg Psychiatry 1993; 56: 98-100. PubMed
Annonse
Annonse